Skip to main content

Tag: Nigeria


DMPA-SC Access Collaborative country briefs

The DMPA-SC Access Collaborative has published a collection of briefs on countries where we have provided focused technical assistance between 2017 and 2021. This includes the Democratic Republic of the Congo, Kenya, Madagascar, Nigeria, Uganda, and Zambia. Each brief describes the country’s introduction and scale-up experiences for DMPA-SC and self-injection, including accomplishments, challenges, innovations, key lessons, factors for success, and plans for the way forward.

 

Institutional author(s): PATH, JSI
Publication date: 2021

Looking back, thinking forward, and scaling up: Insights from the DMPA-SC Access Collaborative

The DMPA-SC Access Collaborative hosted this April 21, 2021 webinar highlighting lessons learned to date through four years of data-driven technical assistance and coordination to ensure that women have increased access to self-injection as a contraceptive option, delivered through informed choice programming. The discussion focused on key topics for the introduction and scale-up of self-injection—and self-care interventions more broadly—at the country level including:

  • Policy and advocacy for new product introduction.
  • How to coordinate scale-up of a new product.
  • Using data to inform program introduction and scale-up.
  • Effective innovations and adaptations in provider training.

This discussion was moderated by Monica Mutesa, Zambia Country Coordinator, DMPA-SC Access Collaborative, PATH. Speakers included:

  • Caitlin Corneliess, Project Director, DMPA-SC Access Collaborative, PATH
  • Adewole Adefalu, Nigeria Country Coordinator, DMPA-SC Access Collaborative, JSI
  • Allen Namagembe, Uganda Deputy Director, DMPA-SC Access Collaborative, PATH
  • Avotiana Rakotomanga, Madagascar Country Coordinator, DMPA-SC Access Collaborative, JSI
  • Alain Kabore, Regional Technical Advisor, DMPA-SC Access Collaborative, PATH

For more information, please contact FPoptions@path.org.

Institutional author(s): PATH, JSI
Publication date: April, 2021

Introducing the Next Generation Injectable in Nigeria

In Nigeria, 20% of women wish to use family planning and reproductive health services, but do not have access to them (USAID 2016). While family planning services and products are available at many public and private facilities, only 11% of women nationwide currently use a modern contraceptive method (NPC 2014). Along with male condoms and pills, injectables are among the most popular methods. However, they are more difficult to access because a trained healthcare worker must administer it with a needle and syringe. Launched in Nigeria in 2014, Sayana® Press is an all-in-one injectable contraceptive designed to overcome barriers to accessing family planning. The unique injection system eliminates the need for a needle and syringe, and enables health workers to administer the injection with basic training. With its ease of application and efficacy, widely distributing Sayana Press is the latest effort to expand contraceptive choice and access for all Nigerian women.

Institutional author(s): DKT Nigeria
Publication date: November, 2022

DMPA-SC policy and regulatory advocacy landscape

This policy landscape can be leveraged by applicants interested in applying to the DMPA-SC Regulatory Advocacy Catalytic Opportunity Fund (COF). The landscape was originally developed in 2020 to understand policies and regulations, including over-the-counter regulations, that impact women’s access to DMPA-SC and identify short- and long-term advocacy opportunities. In 2022, it was refreshed to understand policy shifts and additional advocacy opportunities in a subset of 12 of the original 18 countries currently eligible for the Regulatory Advocacy COF. Insights from the policy landscape have informed the design and eligibility criteria of the Regulatory Advocacy COF, proactively identified opportunities, and provided frameworks and guidance for interested applicants.

Institutional author(s): Clinton Health Access Initiative (CHAI)
Publication date: 2022

Report

DMPA-SC overbranding and overpackaging in private and social marketing sectors

The desire for private sector family planning programs to have the ability to overbrand/overpackage the Pfizer Inc. DMPA-SC product, Sayana® Press, has existed since initial product introduction planning discussions among global partners in 2008–2009. The PATH-JSI DMPA-SC Access Collaborative solicited input from the team’s regional technical advisors, country coordinators, and local partners to better understand the status of overbranding, and any related advocacy­­, in the countries where we work.

Institutional author(s): PATH, JSI
Publication date: July, 2022

Training supply recommendations for DMPA-SC rollout

DMPA-SC is a three-month injectable contraceptive that is easy to use and uniquely suited for self-injection. Demonstration and practice injections are a key part of training programs for both health workers and self-injection clients. Based on lessons learned in five countries, this memo summarizes PATH’s recommendations regarding devices for injection demonstration and practice, injection practice models, and waste disposal.

Institutional author(s): PATH
Publication date: March, 2022

Self-injection in the private sector: Promoting policies for progress

The private sector holds great potential to reduce unmet need for family planning, and many countries are poised to adopt a total market approach for increasing contraceptive access through private pharmacies and drug shops. Policies supporting scale-up of family planning service provision and expanding method options such as DMPA-SC self-injection, must be prioritized in these entities.

The PATH-JSI DMPA-SC Access Collaborative and partners have gained valuable insights with relevance to private sector engagement on self-injection. This webinar held February 15, 2022 highlighted lessons learnt, challenges, recommendations, and considerations for policies supporting private sector engagement in self-injection in different country contexts. Specific topics included:

  • Financing and commodity production ecosystems
  • Procurement and supply chains
  • Service delivery and programming
  • Data reporting and monitoring
  • Advocacy
  • Demand generation

The discussion was moderated by Allen Namagembe, Deputy Project Director, Uganda DMPA-SC Access Collaborative, PATH.

Panelists:

  • Dr. Kayode Afolabi, Director and Head, Reproductive Health Division, Federal Ministry of Health, Nigeria
  • Dr. Daniella Munene, Member, National Executive Committee, Pharmaceutical Society of Kenya
  • Dr. Hortense Randrianaivo, President, Association of Pharmacists of Madagascar
  • Mr. Célestin Compaore, Regional Project Director, DMPA-SC, Jhpiego, Burkina Faso

Institutional author(s): PATH, JSI, Jhpiego, Nigeria Federal Ministry of Health, Pharmaceutical Society of Kenya, Association of Pharmacists of Madagascar
Publication date: February, 2022

Insight synthesis report on DMPA-SC self-injection

This report distills more than a year of programmatic research findings, looking at self-injection from a user journey perspective to analyze what drives consumer and provider decisions and attitudes. It reflects the unique perspectives of DMPA-SC self-injection early adopters and prospective users across Uganda and Nigeria. The report outlines how women perceive their own power, what makes self-injection convenient for them, who they trust as partners in their de-medicalized contraceptive experience, and more.

Institutional author(s): Population Services International (PSI)
Publication date: September, 2021

DMPA-SC country data dashboard

The country dashboard is a visual presentation of key data for a select list of priority countries; it provides a snapshot of the state and stage of DMPA-SC introduction/scale-up, allowing stakeholders to assess progress, identify roadblocks, guide course corrections, and inform decisions.

Institutional author(s): PATH
Publication date: August, 2020

Injectable Contraceptive Assessment in Uganda and Nigeria

This webinar will present the key findings from a two-phased research program funded by The Bill and Melinda Gates Foundation, in Nigeria and Uganda. The first phase was a qualitative exploration within Focus Group discussions (total sample n=600 in 100 Focus Groups (n=6 per FG) across 8 different FG types and split across 2 urban and 2 rural settings per country) with women and their male partners (separately). The second phase was a quantitative survey with women (total sample n=1,410 women) split across 4 regions within each country. The research explored several central topics: the various contraceptive journeys and experiences of women and their male partners, including satisfied and discontinued users of the injectable contraceptive (Depo), satisfied users of the DMPA-SC (Sayana Press), naïve users of modern contraceptive and those using traditional methods. Factors which lead to discontinuation and experiences with/perception of side effects. Gauge level of acceptability and preference for certain injectable attributes, in particular the impact of DMPA-SC 3 months or a potential 6 month injectable on likelihood to try. We tested 3 fully developed concepts and vary the most impactful features from phase 1 with women. Develop a forecast model for the Depo, DMPA-SC 3 month and a potential 6 month injectable in Nigeria and Uganda.

Institutional author(s): Reproductive Health Supplies Coalition (RHSC), Routes2Results
Publication date: November, 2019